Leman Biotech Co., Ltd. (“Leman Biotech”), a clinical-stage biotechnology company focused on the research, development, production, and commercialization of innovative metabolic immunotherapies, announced a significant clinical progress made in its investigator-initiated trial (IIT) for metabolically armed CD19 CAR-T cell therapy (Meta10-19 injection). The first enrolled systemic lupus erythematosus (SLE) patient achieved “medication-free DORIS remission” (complete remission without ongoing treatment) after receiving a single infusion of Meta10-19 injection at a dose of only 1‰ (one-thousandth) of the standard commercial CAR-T dose (2×106 CAR-T cell/kg). The patient discontinued all SLE-related medications following clinical assessment.
